Abstract: The invention provides methods for reducing undesired immune responses, such as anti-drug antibody (ADA) responses and other T- and/or B-cell-mediated immune responses, in patients by using treatment with methotrexate.

Abstract: The invention provides methods for reducing undesired immune responses, such as anti-drug antibody (ADA) responses and other T- and/or B-cell-mediated immune responses, in patients by using treatment with methotrexate.

Abstract: Described herein include compositions and methods that can be useful for inhibiting activity of Tfh cells, B-cells, germinal centers, extrafollicular T and B-cells, and/or ectopic follicular structures; and/or in treating diseases such as autoimmune diseases.

Abstract: The invention provides methods for reducing undesired immune responses, such as anti-drug antibody (ADA) responses and other T- and/or B-cell-mediated immune responses, in patients by using treatment with methotrexate.

Abstract: A display board assembly includes a map rail and a supplemental display board mounted thereto. The map rail includes a top track defined by a top support rail and a top guard rail, and a bottom track defined by a bottom support rail and a bottom guard rail. The supplemental display board includes a wheeled mounting assembly on a rear surface thereof, the wheeled mounting assembly including: a top wheel forced to engage the top track and confined by the top guard rail, and a bottom wheel forced to engage the bottom track and confined by the bottom guard rail, wherein the supplemental display board is slidable on the top wheel and bottom wheel to different lateral positions on the map rail.

Abstract: A display board assembly includes a map rail and a supplemental display board mounted thereto. The map rail includes a top track defined by a top support rail and a top guard rail, and a bottom track defined by a bottom support rail and a bottom guard rail.

Abstract: The invention provides methods for reducing undesired immune responses, such as anti-drug antibody (ADA) responses and other T- and/or B-cell-mediated immune responses, in patients by using treatment with methotrexate.

Abstract: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II.